BALTIMORE--(BUSINESS WIRE)--
At the 62nd ASMS Conference on Mass Spectrometry and Allied
Topics today, Bruker Corporation (NASDAQ:BRKR) today announced mass
spectrometry-based product introductions for life-science research and
proteomics, for clinical research, for pharma/biopharma/CRO customers,
as well as for applied and industrial markets. The new systems and
solutions are designed to deliver confident analyses with significantly
enhanced performance, productivity and versatility.
impact(TM) II Mass Spectrometer (Photo: Business Wire)
Major Bruker Innovations at ASMS 2014:
-
New impact II ™ ultra-high resolution QTOF mass spectrometer
with industry-leading further performance improvements
-
A breakthrough, new 21 Tesla magnet for ultra-high field Fourier
Transform Mass Spectrometry (FTMS), described in a separate joint
press release together with NHMFL
-
Opening the next chapter in proteomics, the unique impact II
now enables for the first time ever fast, intact protein profiling of
over 1,000 proteoforms in a single, less than 30 minute UHPLC-UHR-QTOF
run
-
New multi-OMICS platform increasing productivity, versatility, and
deeper biological insights, including full MaxQuant software
support and new Compass™ PathwayScreener™ software
-
New ToxScreener™ solution for comprehensive forensic toxicology
on unknowns
-
European launch of Toxtyper™ 1.1, a robust and easy to use
forensic and clinical research solution for routine, fast, push-button
toxicology on approximately 900 compounds
-
ASMS debut of new autoflex™ speed MALDI TOF(/TOF) system with
Bruker 2 kHz smartbeam™-II laser to enhance productivity in
protein analysis, MALDI imaging and MALDI Biotyper applications
The new research capabilities, analytical utility and productivity will
be presented in Bruker’s ASMS users’ symposium, breakfast workshops, and
hospitality suite with emphasis on the following market/applications
areas: systems biology, proteomics and metabolomics; biologics &
pharmaceuticals; MALDI molecular imaging for pathology research and drug
development; petroleomics, energy and industrial applications; applied
markets including food safety, forensics and toxicology; as well as MALDI
Biotyper-based clinical microbiology. The following sections
describe the new Bruker products in more detail:
impact™ II Mass Spectrometer
The new impact II system is the latest innovation in Bruker’s
unique UHR-QTOF (ultra-high resolution Qq-time-of-flight) mass
spectrometry product line, now with industry-leading >50,000
Full-Sensitivity Resolution (FSR). It offers further enhanced analytical
performance levels for all applications where trace analysis from
complex, high-background matrices is a challenge – such as proteomics,
biomarker research, identification of impurities, or residue screening.
Due to its industry-leading sensitivity, broad mass-transfer ion optics
and fast 50 Gbit/sec sampling technology, a dynamic range of 5 orders of
magnitude is achieved at UHPLC speeds, with up to 50 Hz spectrum
acquisition. The impact II features industry-leading isotopic
pattern accuracy, a prerequisite for automated, reliable molecular
formula determination of low abundance compounds in nano- and UHPLC
peaks.
The enhanced capabilities and versatility of this novel UHR-QTOF drive
more productivity for all accurate mass , high dynamic range
applications in academia and industry, including:
-
Faster and cost-effective analysis of sub-units of monoclonal
antibodies, which can now be fully isotope resolved.
-
Sustainable identification and quantification performance for in-depth
quantitative analysis of proteomics samples, including bottom-up
proteomics, glycomics and the identification of PTMs
-
High-throughput proteoform screening of intact proteins with isotopic
resolution up to 30 kDa. This unique assay allows the screening of
well over 1,000 proteoforms in a single 20-30 min UHPLC-UHR-QTOF run.
This breakthrough in proteomics is expected to provide an enabling
technology for accelerated biomarker identification and validation,
and for faster progress towards clinical proteomics.
-
Deep insight into complex metabolomics samples in targeted and
non-target analysis by integrated workflows using ProfileAnalysis™
software plus the new Compass PathwayScreener software to pinpoint
biomarkers.
-
Better selectivity and specificity for the new Bruker solution in
forensic toxicology, ToxScreener, which comes with accurate
mass libraries developed together with leading forensic toxicology
laboratories.
-
Unique Instant Expertise™ software for intelligent
self-optimizing MS/MS acquisition to establish optimal experimental
conditions independent of sample amount or complexity. This translates
into higher productivity and expert-caliber results - the first time.
These features ensure that the impact II delivers the
fastest time-to-success for customers across a broad applications
ranging from small molecule identification and characterization; to food
safety, forensic and toxicology screening, metabolomics,
pharmaceuticals, and bottom-up proteomics, proteoform screening to
antibody analysis.
Multi-OMICS Knowledge Generation Platform
Bruker is driving the quest for deeper insights and taking ‘omics’
knowledge generation to new heights with the new additions improving
productivity and versatility in areas such as bottom-up proteomics,
glycomics, quantitative proteomics, intact protein analysis,
post-translational modifications and metabolomics.
“We have been using the Impact since almost a year for routine
shot-gun bottom-up proteomics. In combination with the CaptiveSpray
nanoBooster, the instrument has provided an excellent level of
sustainable performance, being capable of delivering untouched
performance for over 6-8 weeks of 24/7 use. This is of tremendous
importance for the success of our label-free measurement campaigns,”
said Professor Alain Van Dorsselaer, LSMBO in Strassbourg, France.
To strengthen its bioinformatics platform, Bruker has collaborated with
developers in the group of Professor Matthias Mann to add support for
Bruker UHR-QTOF data to the state-of-the-art quantitative proteomics MaxQuant
software designed for analyzing large mass-spectrometric data sets.
It is specifically aimed at high-resolution MS data. Several labeling
techniques as well as label-free data processing workflows are supported
and in addition MaxQuant enables researchers to utilize the full
potential of mass spectrometry driven proteomics in multi-OMICS
approaches.
In metabolomics there is an increasing need for efficient data
processing tools, and Bruker has strengthened its bioinformatics
offering with Compass™ PathwayScreener software to provide a new
layer of insight into metabolomics samples. With the new Compass
PathwayScreener, users can get twice the results, performing
pathway-driven, targeted metabolomics analysis on the same dataset used
for non-targeted data mining. The PathwayScreener workflow can be
integrated with Bruker’s market-leading multi-OMICS bioinformatics
platform ProfileAnalysis™ for non-targeted metabolomics and label
free proteomics studies.
Professor Jörn Kalinowski, at the Center for Biotechnology in Bielefeld,
Germany, stated: “Using Compass PathwayScreener we were able to
elucidate novel influences of mutants on metabolic networks in
Corynebacterium glutamicum.”
In addition, Bruker is collaborating with the University of Alberta to
facilitate the development of high-resolution tandem MS libraries for
improved workflows in metabolomics. Professor Liang Li explained: “As a
co-PI of the Human Metabolome Database (HMDB) project, my laboratory
generated the original MS/MS spectral library of about 800 human
metabolites using low-resolution triple quadrupole mass spectrometry. We
are delighted to collaborate with Bruker to produce a new Human
Metabolite MS/MS spectral library with much improved spectral quality.
This library, along with an automated acquisition and processing
strategy, allows users to identify metabolites very quickly with high
confidence.”
Dr. Ole Vorm, the Bruker Daltonics Vice President for the Life-Science
Research & Proteomics business unit, commented: “The new products
deliver outstanding and robust performance in a very accessible and
cost-effective platform. We are conscious of enhancing the reach and
capabilities of UHF-QTOF and nano-ESI such that we make this innovative
technology readily available and accessible - also for biologists who
may not be mass-spec experts. Finally, our proteomics customers are
excited about our breakthrough, rapid proteoform screening technology on
the impact II, as well as its about 50% higher resolution for
bottom-up proteomics, at full sensitivity and under UHPLC fast analysis
conditions.”
ToxScreener, a Forensic Toxicology Solution based on
Accurate Mass, High Dynamic Range LC-MS/MS
The ToxScreener, a new accurate mass, high dynamic range forensic
toxicology solution for Bruker QTOF systems, incorporates broadband CID
(bbCID) acquisition to provide a rapid and reliable way for scientists
to confidently screen for hundreds or even thousands of known or
previously unknown compounds of forensic relevance, delivering the
highest degree of confidence, and data that is defensible in court.
The ToxScreener enables forensic toxicologists to keep up with
the detection and identification of both the ‘traditional, established’
drugs of abuse, as well to detect new designer drugs that are rapidly
emerging across the globe. At the heart of the ToxScreener, is a
high quality, accurate mass database covering drugs of forensic
relevance allowing users to attain enhanced levels of confirmation for
conclusive identification compared to alternative screening techniques.
The Bruker ToxScreener bbCID accurate mass forensic database was
developed in close collaboration with toxicologists at the forensic
institutes at the universities of Freiburg, Germany and Helsinki,
Finland.
Professor Ilkka Ojanperä of the Laboratory of Forensic Toxicology at the
University of Helsinki, said: “We have applied the bbCID concept using
Bruker LC-TOF-MS for general forensic drug screening in urine since
2010. In 2013, we switched to the newest UHPLC-UHR-QTOF mass
spectrometry technology to attain enhanced sensitivity for
drugs-of-abuse and designer drug forensic screening, covering critical
low concentration compounds like THC acid, buprenorphine, LSD, and
synthetic cannabinoids. This approach has been well received amongst our
customers, being an even bigger success than we expected, such that
immunological methods in our laboratory have now been replaced by the
Bruker QTOF bbCID workflow. The bbCID concept has been carefully
validated against spectral library comparison, and it has proven to
deliver equal confidence, but with a much higher efficiency,
significantly increasing our productivity. Our forensic screening method
has now been accredited by the Finnish Accreditation Service.”
High-throughput, Robust Toxtyper 1.1 Solution Automatically
Analyzes for 900 Known Toxicology Target Compounds in 12 Minutes
The new Toxtyper 1.1 routine analytical solution includes novel
library identification algorithms and reporting with a high-quality
library update to over 900 target compounds. In addition, the Toxtyper
1.1 workflow now also comes with a targeted drugs-of-abuse
sub-library. Key technologies to achieve robust and reliable toxicology
identification performance include continuous, zero-delay
positive/negative ion switching, high MS/MS specificity and novel,
on-the-fly MS3 confirmation. The new Toxtyper 1.1 search
algorithms now also are fully compatible with the recently published
“Maurer/Wissenbach/Weber LC-MSn library of Drugs, Poisons and
their Metabolites”, an ion trap library which holds over 1,000 parent
compounds and 2,700 metabolites.
Novel software tools for automated assignment of structures to fragment
ions offer additional metabolites identification and structure
verification by MSn. Toxtyper 1.1 now supports sample
preparation SOPs for high sensitivity detection of drugs in urine and
serum. Toxtyper is a Research Use Only solution presently
available only in Europe in selected countries. For more information on
the amaZon speed mass spectrometer, please visit www.bruker.com
ASMS Debut of autoflex™ speed MALDI-TOF(/TOF) with 2 kHz Smartbeam™
Laser
The updated autoflex speed mass spectrometer incorporates
of numerous advancements to further enhance data quality, acquisition
speed, class-leading mass and dynamic range, all with robust and
efficient performance. It further extends the applications of MALDI
TOF/TOF in protein sequencing, biomarker discovery, polymer analysis,
lipid and glycan analysis, molecular imaging, as well as in
high-throughput MALDI Biotyper microbiological identification.
The autoflex speed incorporates the patented smartbeam™-II
laser, now with up to 2 kHz repetition rate and true-pixel image
resolution at 20 µm, along with other features that enhance its
capabilities including:
-
Unique FAST-SRM mode for single reaction monitoring in imaging
drugs and metabolites in tissue.
-
Expanded high-resolution mass range for polymers and top-down, intact
protein sequencing for long sequence readouts.
-
FlashDetector™ technology to increase resolution and
prevent signal saturation for complex samples
-
Self-cleaning Ion Source cleans the source in minutes to improve
up-time with minimal operator maintenance.
-
Optimized software packages for numerous applications e.g. protein,
peptide or polymer analysis, as well as MALDI imaging, clinical
research and the MALDI Biotyper IVD-CE workflow.
About Bruker Corporation
Bruker Corporation is a leading provider of high-performance scientific
instruments and solutions for molecular and materials research, as well
as for industrial and applied analysis. For more information about
Bruker Corporation (NASDAQ:BRKR), please visit www.bruker.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140616005495/en/
Source: Bruker Corporation